Instrumental activities of daily living in neuro-oncology: International validation of the EORTC IADL-BN32 questionnaire.

Autor: Oort Q; Cancer Center Amsterdam, Brain Tumor Center, Amsterdam, the Netherlands; Department of Neurology & Brain Tumor Center Amsterdam, Amsterdam University Medical Centers (Location VUmc), Amsterdam, the Netherlands., Reijneveld JC; Cancer Center Amsterdam, Brain Tumor Center, Amsterdam, the Netherlands; Department of Neurology & Brain Tumor Center Amsterdam, Amsterdam University Medical Centers (Location VUmc), Amsterdam, the Netherlands; Department of Neurology, Stichting Epilepsie Instellingen Nederland (SEIN), Heemstede, the Netherlands., Sikkes SAM; Alzheimer Center, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands; Vrije Universiteit Amsterdam, Faculty of Behavioural and Movement Sciences (FGB), Department of Clinical Developmental & Clinical Neuropsychology, Amsterdam, the Netherlands., Koekkoek JAF; Department of Neurology, Haaglanden Medical Center, The Hague, the Netherlands; Department of Neurology, Leiden University Medical Center, Leiden, the Netherlands., Boele F; Leeds Institute of Medical Research, St James's University Hospital, Leeds LS9 7TF, United Kingdom; Leeds Institute of Health Sciences, Faculty of Medicine and Health, University of Leeds, Leeds LS2 9JT, United Kingdom., Young T; East & North Hertfordshire NHS Trust Incorporating Mount Vernon Cancer Centre, Northwood, United Kingdom., Brannan C; East & North Hertfordshire NHS Trust Incorporating Mount Vernon Cancer Centre, Northwood, United Kingdom., Chalk T; East & North Hertfordshire NHS Trust Incorporating Mount Vernon Cancer Centre, Northwood, United Kingdom., Talacchi A; Department of Neurosurgery, Azienda Ospedaliera San Giovanni Addolorata, Roma, Italy., Mazzotta A; Department of Neurosurgery, Azienda Ospedaliera San Giovanni Addolorata, Roma, Italy., Narita Y; Department of Neurosurgery and Neuro-oncology, National Cancer Center Hospital, Tokyo, Japan., Sato H; Department of Neurosurgery and Neuro-oncology, National Cancer Center Hospital, Tokyo, Japan; Department of Nursing, Teikyo Heisei University, Tokyo, Japan., Miyakita Y; Department of Neurosurgery and Neuro-oncology, National Cancer Center Hospital, Tokyo, Japan; Cancer Institute Hospital of JFCR, Tokyo, Japan., Shamieh O; Department of Palliative Medicine, King Hussein Cancer Center (KHCC), Amman, Jordan; School of Medicine, University of Jordan, Amman, Jordan; Center for Palliative & Cancer Care in Conflict (CPCCC), KHCC, Amman, Jordan., Alrjoob W; Center for Palliative & Cancer Care in Conflict (CPCCC), KHCC, Amman, Jordan., Pace A; Neuro-Oncology Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy., Petranovic D; Department of Hematology, Clinical Hospital Center Rijeka, Rijeka, Croatia., Ploh M; Department of Hematology, Clinical Hospital Center Rijeka, Rijeka, Croatia., Capela A; Associação de Investigação de Cuidados de Suporte em Oncologia (AICSO), Portugal; Centro Hospitalar Vila Nova de Gaia, Espinho, Portugal., Silva J; Associação de Investigação de Cuidados de Suporte em Oncologia (AICSO), Portugal; Centro Hospitalar Vila Nova de Gaia, Espinho, Portugal., Hjermstad MJ; European Palliative Care Research Centre (PRC), Department of Oncology, Oslo University Hospital and Institute of Clinical Medicine of University of Oslo, Oslo, Norway; Regional Advisory Unit for Palliative Care, Department of Oncology, Oslo University Hospital, Oslo, Norway., Purkart TU; Department of Neurology and Neuroradiology, Vascular and Interventional Radiology, Medical University of Graz, Austria., Seidel C; Department of Radiation Oncology, University of Leipzig Medical Center, Leipzig, Germany., Talhi N; Department of Radiation Oncology, University of Leipzig Medical Center, Leipzig, Germany., Pichler J; Institut für Innere Medizin mit Neuroonkologie, Kepler Universitätsklinikum GmbH, Linz, Austria., Höllmüller I; Institut für Innere Medizin mit Neuroonkologie, Kepler Universitätsklinikum GmbH, Linz, Austria., Brown L; John Eastwood Hospice, Sutton-in-Ashfield, United Kingdom., Hand M; John Eastwood Hospice, Sutton-in-Ashfield, United Kingdom., Klein M; Cancer Center Amsterdam, Brain Tumor Center, Amsterdam, the Netherlands; Department of Medical Psychology, Amsterdam University Medical Centers (Location VUmc), Amsterdam, the Netherlands., Aaronson NK; Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Uitdehaag BMJ; Department of Neurology & Brain Tumor Center Amsterdam, Amsterdam University Medical Centers (Location VUmc), Amsterdam, the Netherlands., Taphoorn MJB; Department of Neurology, Haaglanden Medical Center, The Hague, the Netherlands; Department of Neurology, Leiden University Medical Center, Leiden, the Netherlands. Electronic address: m.j.b.taphoorn@lumc.nl., Dirven L; Department of Neurology, Haaglanden Medical Center, The Hague, the Netherlands; Department of Neurology, Leiden University Medical Center, Leiden, the Netherlands.
Jazyk: angličtina
Zdroj: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2024 Sep 21; Vol. 212, pp. 114335. Date of Electronic Publication: 2024 Sep 21.
DOI: 10.1016/j.ejca.2024.114335
Abstrakt: Background: Neurocognitive impairments are common in patients with a brain tumour, and may negatively impact on functioning in daily life, particularly on instrumental activities of daily living (IADL). The EORTC IADL-BN32 questionnaire was developed to measure IADL in this patient population.
Methods: In this international validation study, we evaluated the EORTC IADL-BN32 questionnaire on several psychometric properties in a large sample of patients with a primary or metastatic brain tumour. We administered the 32-item questionnaire three times: at 'baseline', after 2 weeks and after 3 months. Procedures were in accordance with EORTC Quality of Life Group module development guidelines.
Results: In total, 326 patients participated in the study. A bifactor scale structure showed satisfactory model fit measures, with five multi-item scales and two single items, and an IADL sum score. The internal consistency of the multi-item scales ranged from good to excellent (range Cronbach's α: 0.86-0.97). We found significant differences in scale scores between patients with and without neurocognitive impairments or complaints, supporting the construct validity. Initial cross-cultural validity analyses showed indications of item response biases for certain items. Analyses indicated moderate to good test-retest agreement (intraclass correlation coefficient > 0.70) between baseline and the 2-week follow-up assessment for all but one scale. Deterioration of EORTC IADL-BN32 scale scores were consistent with clinically relevant deterioration on other functional measures with small to large effect sizes, however, subgroup sample sizes were small.
Conclusion: Overall, the EORTC IADL-BN32 questionnaire exhibited adequate to excellent psychometric properties. Cross-cultural validity and responsiveness should be further explored.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: